Incyte Corporation $INCY Shares Bought by Edgestream Partners L.P.

Edgestream Partners L.P. grew its holdings in Incyte Corporation (NASDAQ:INCY) by 1,318.0% during the first quarter, HoldingsChannel reports. The firm owned 157,472 shares of the biopharmaceutical company’s stock after acquiring an additional 146,367 shares during the period. Incyte comprises about 0.5% of Edgestream Partners L.P.’s investment portfolio, making the stock its 7th biggest holding. Edgestream Partners L.P.’s holdings in Incyte were worth $14,821,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in INCY. Jacobi Capital Management LLC grew its position in shares of Incyte by 0.9% in the fourth quarter. Jacobi Capital Management LLC now owns 10,613 shares of the biopharmaceutical company’s stock valued at $1,048,000 after purchasing an additional 99 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its position in Incyte by 0.5% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 18,870 shares of the biopharmaceutical company’s stock worth $1,864,000 after buying an additional 100 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in Incyte by 7.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,628 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 113 shares in the last quarter. Bank of Nova Scotia boosted its stake in Incyte by 0.7% during the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company’s stock worth $1,160,000 after buying an additional 124 shares during the last quarter. Finally, Perbak Capital Partners LLP boosted its stake in Incyte by 2.5% during the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company’s stock worth $449,000 after buying an additional 129 shares during the last quarter. 96.97% of the stock is currently owned by institutional investors and hedge funds.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Strong Q2 results: Incyte reported $1.67 billion in revenue, up 37.7% year over year, and adjusted earnings of $3.09 per share versus the $2.20 consensus estimate. Growth was led by Jakafi, Opzelura and the company’s hematology and oncology portfolio. INCY Q2 Earnings and Revenues Beat
• Positive Sentiment: Higher full-year outlook: Management raised 2026 total net-sales guidance to $5.13 billion-$5.26 billion from $4.77 billion-$4.94 billion. Opzelura guidance was increased to $1.05 billion-$1.10 billion, helped by a CMS settlement expected to contribute approximately $300 million-$310 million. Incyte Raises 2026 Sales Forecast
• Positive Sentiment: Analyst target increases: HC Wainwright raised its target to $150 from $140 and kept a Buy rating, while BMO lifted its target to $130 from $112. Analysts cited stronger commercial momentum, pipeline progress and a broader product base. Analysts Raise Incyte Forecasts
• Neutral Sentiment: Incyte expects 10 clinical data readouts, including four registrational trials, in the second half of 2026. These could create catalysts but also increase clinical execution risk.
• Negative Sentiment: UBS reiterated a Hold rating with an unchanged $113 target, arguing that the recent rally limits near-term upside. A separate analysis also downgraded the stock from Buy to Hold after its substantial advance. UBS Reiterates Hold on Incyte
• Negative Sentiment: The Opzelura benefit includes a $246 million one-time, non-cash accounting benefit from the CMS settlement, making some of the guidance increase less indicative of recurring operating growth. Several company insiders have also sold shares without reported purchases in the past six months.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on INCY. Royal Bank Of Canada upped their target price on Incyte from $99.00 to $109.00 and gave the company a “sector perform” rating in a report on Wednesday. Truist Financial lifted their price target on Incyte from $103.00 to $105.00 and gave the stock a “hold” rating in a report on Monday, June 22nd. TD Cowen reissued a “hold” rating on shares of Incyte in a research report on Tuesday, June 9th. Sanford C. Bernstein began coverage on shares of Incyte in a report on Thursday, May 21st. They issued a “market perform” rating and a $99.00 price objective for the company. Finally, Barclays raised their price objective on shares of Incyte from $134.00 to $139.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $117.74.

Incyte Stock Performance

NASDAQ INCY opened at $127.10 on Thursday. The stock has a market cap of $25.39 billion, a PE ratio of 16.19, a P/E/G ratio of 1.13 and a beta of 0.76. The company has a current ratio of 4.53, a quick ratio of 3.60 and a debt-to-equity ratio of 0.01. Incyte Corporation has a twelve month low of $73.81 and a twelve month high of $132.60. The stock has a fifty day simple moving average of $108.59 and a 200-day simple moving average of $102.00.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.50 billion. Incyte had a return on equity of 29.93% and a net margin of 27.71%.The company’s quarterly revenue was up 37.7% on a year-over-year basis. During the same period last year, the company earned $1.57 EPS. Equities analysts anticipate that Incyte Corporation will post 6.9 earnings per share for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.